Rieke Fischer

TH Köln - University of Applied Sciences — Germany

Medicine · Health Sciences

19h-index2.1kcitations89works13.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(57), Cancer Genomics and Diagnostics(25), Lung Cancer Research Studies(13), Colorectal Cancer Treatments and Studies(11), Cancer Immunotherapy and Biomarkers(10)

Publications89 total

Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring <i>KRAS</i> G12V mutations
Clinical Cancer Research·2025
Brief Report: MET driven resistance to sotorasib in KRAS G12C-mutant Non-small cell lung cancer and response to combined KRAS and MET inhibition
JTO Clinical and Research Reports·2025· 1 citedOpen Access
EATON: A phase I trial of nazartinib (EGF816) and trametinib in EGFR-mutant (EGFRmut) non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology·2025· 1 cited
Upregulation and epigenetic modification of the creatine transporter SLC6A8 in non-small cell lung cancer.
PubMed·2024
Molecular and clinical characteristics of patients with non-small-cell lung cancer (NSCLC) harboring <i>KRAS</i> G12V mutations.
Journal of Clinical Oncology·2024
BIOLUMA: A phase II trial of nivolumab and ipilimumab in lung cancer—Results from the SCLC TMB<sup>high</sup> cohort.
Journal of Clinical Oncology·2024· 1 cited
Evolutionary trajectories of small cell lung cancer under therapy
Nature·2024· 90 citedOpen Access
Clinical characteristics and treatment outcome of patients with advanced non-small-cell lung cancer (NSCLC) and FGFR fusions.
Journal of Clinical Oncology·2023· 2 cited
Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion–Positive Pancreatic Adenocarcinoma: A Case Report
JCO Precision Oncology·2023· 3 cited
Supplementary Figure 3 from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
2023Open Access
Supplementary Figure 4 from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
2023Open Access
Data from Clinical and Pathological Characteristics of &lt;i&gt;KEAP1&lt;/i&gt;- and &lt;i&gt;NFE2L2&lt;/i&gt;-Mutated Non–Small Cell Lung Carcinoma (NSCLC)
2023Open Access
Supplementary Figure 2 from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
2023Open Access
Supplemental Table 8 from Clinical and Pathological Characteristics of &lt;i&gt;KEAP1&lt;/i&gt;- and &lt;i&gt;NFE2L2&lt;/i&gt;-Mutated Non–Small Cell Lung Carcinoma (NSCLC)
2023Open Access
Supplementary Figure 1 from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
2023Open Access
Supplementary Figure 3 from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
2023Open Access
Supplement from Clinical and Pathological Characteristics of &lt;i&gt;KEAP1&lt;/i&gt;- and &lt;i&gt;NFE2L2&lt;/i&gt;-Mutated Non–Small Cell Lung Carcinoma (NSCLC)
2023Open Access
Supplement from Clinical and Pathological Characteristics of &lt;i&gt;KEAP1&lt;/i&gt;- and &lt;i&gt;NFE2L2&lt;/i&gt;-Mutated Non–Small Cell Lung Carcinoma (NSCLC)
2023Open Access
Supplementary Figure 4 from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
2023Open Access
Data from Clinical and Pathological Characteristics of &lt;i&gt;KEAP1&lt;/i&gt;- and &lt;i&gt;NFE2L2&lt;/i&gt;-Mutated Non–Small Cell Lung Carcinoma (NSCLC)
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Sebastian Michels(33), Matthias Scheffler(32), Sabine Merkelbach‐Bruse(31), Reinhard Büttner(29), Lucia Nogová(24), Andreas H. Scheel(21), Richard Riedel(21), Jürgen Wolf(20), Jana Fassunke(19), Juergen Wolf(14), Lukas C. Heukamp(13), Carina Heydt(13), Christian Grohé(11), Reinhard Buettner(10), Michaela A. Ihle(10), Roman K. Thomas(10), Anna Kron(10), Sophia Koleczko(10), Anna Eisert(10), Martin Sebastian(10)